HIF1A and liver cancer: In conclusion, this study provides strong evidence that CK may exert therapeutic effects by inhibiting the HIF-1α-mediated glycolysis pathway by downregulating the expression of Bclaf1 in liver cancer cells, and thereby inhibiting cell proliferation and cancer progression in the hypoxic microenvironment observed in liver cancer.